Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
How to invest
How to turn $20,000 into $130,000 in 10 years with ASX shares
Growth Shares
10 top ASX shares to buy for 2020
Growth Shares
3 explosive growth shares I want in my portfolio
Growth Shares
Why I would buy and hold Cochlear and these ASX healthcare shares
Share Market News
Warning: The Australian dollar and gold price are now flashing red at GFC levels
Growth Shares
The Cochlear share price just hit an all-time high: Too late to invest?
Share Market News
Wisetech, Altium, Pro Medicus, Nearmap, Xero: Bubble or ultimate growth shares?
Share Market News
Goldman Sachs rates ResMed shares a buy, claims still cheaper than Cochlear, CSL
Growth Shares
Where to invest $5,000 in ASX 200 shares in August
Share Market News
Here's why ResMed Inc. shares just hit a record high on its full year results
Growth Shares
3 quality ASX growth shares to buy in August
Share Market News
Macquarie picks the reporting season's heroes and zeros
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
